MX2018003317A - Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos. - Google Patents

Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.

Info

Publication number
MX2018003317A
MX2018003317A MX2018003317A MX2018003317A MX2018003317A MX 2018003317 A MX2018003317 A MX 2018003317A MX 2018003317 A MX2018003317 A MX 2018003317A MX 2018003317 A MX2018003317 A MX 2018003317A MX 2018003317 A MX2018003317 A MX 2018003317A
Authority
MX
Mexico
Prior art keywords
cells
modified
fugetactic properties
fugetactic
properties
Prior art date
Application number
MX2018003317A
Other languages
English (en)
Inventor
C Poznansky Mark
Vianello Fabrizio
Original Assignee
The General Hospital Corp Dba Massacsetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corp Dba Massacsetts General Hospital filed Critical The General Hospital Corp Dba Massacsetts General Hospital
Publication of MX2018003317A publication Critical patent/MX2018003317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona métodos ex vivo para hacer composiciones de células Inmunes modificadas por ejemplo, célula T, las composiciones tienen propiedades generales anti-fuctácticas para el tratamiento efectivo y eficiente de tumores o cánceres en un paciente y composiciones y uso de las mismas.
MX2018003317A 2015-09-18 2016-09-16 Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos. MX2018003317A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562220927P 2015-09-18 2015-09-18
US201562220857P 2015-09-18 2015-09-18
US201662303368P 2016-03-03 2016-03-03
US201662303365P 2016-03-03 2016-03-03
PCT/US2016/052343 WO2017049238A1 (en) 2015-09-18 2016-09-16 Modified t-cells having anti-fugetactic properties and uses thereof

Publications (1)

Publication Number Publication Date
MX2018003317A true MX2018003317A (es) 2018-11-09

Family

ID=58289704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003317A MX2018003317A (es) 2015-09-18 2016-09-16 Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.

Country Status (10)

Country Link
US (1) US20180273897A1 (es)
EP (1) EP3349767A4 (es)
JP (2) JP2018527010A (es)
CN (1) CN108348545A (es)
AU (1) AU2016324303A1 (es)
CA (1) CA2999096A1 (es)
HK (1) HK1259027A1 (es)
IL (1) IL258181A (es)
MX (1) MX2018003317A (es)
WO (1) WO2017049238A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1435433A (zh) * 2002-08-30 2003-08-13 龚小迪 长效广谱的趋化因子受体抑制物
JP2006508697A (ja) * 2002-12-06 2006-03-16 ザ・ジェネラル・ホスピタル・コーポレイション 勾配に暴露された細胞に関する方法および組成物
JP2008519052A (ja) * 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
CN101333531B (zh) * 2008-08-06 2011-09-28 温州医学院 一种CXCR4拮抗剂重组蛋白SDF-1βP2G及其制备方法和应用
US9199028B2 (en) * 2010-01-15 2015-12-01 Memorial Sloan-Kettering Cancer Center Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害

Also Published As

Publication number Publication date
HK1259027A1 (zh) 2019-11-22
EP3349767A1 (en) 2018-07-25
US20180273897A1 (en) 2018-09-27
CN108348545A (zh) 2018-07-31
WO2017049238A1 (en) 2017-03-23
JP2022028682A (ja) 2022-02-16
JP2018527010A (ja) 2018-09-20
IL258181A (en) 2018-05-31
EP3349767A4 (en) 2019-03-20
AU2016324303A1 (en) 2018-04-26
CA2999096A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
TW201613648A (en) Compounds and compositions for immunotherapy
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
NZ766131A (en) Antibodies binding axl
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
MX2017002489A (es) Agentes terapeuticos humanos.
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
SI3460052T1 (sl) Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka
TW201713323A (en) Therapeutic compositions and methods of use thereof
PH12016501838A1 (en) Compounds and their methods of use
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2018003313A (es) Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.
WO2016046759A3 (en) Compositions and methods for treating friedreich's ataxia
MX2018003317A (es) Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.
MX2020002812A (es) Abx196 para usarse en el tratamiento del cancer de vejiga.
PL3319638T3 (pl) Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków